#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

The idiopathic hypereosinophilic syndrome and chronic eosinophilic leukemia


Authors: L. Chrobák;  J. Voglová
Authors‘ workplace: Oddělení klinické hematologie II. interní kliniky Lékařské fakulty UK a FN, Hradec Králové, přednosta prof. MUDr. Jaroslav Malý, CSc.
Published in: Vnitř Lék 2005; 51(12): 1385-1393
Category: Review

Předneseno na XIX. olomouckých dnech s mezinárodní účastí ve dnech 15. - 18. června 2005.

Overview

Idiopathic hypereosinophilic syndrome is a heterogenous group of hematological disorders characterized by eosinophilia (> 1.5 x 109/l) persistent for more than 6 months, exclusion of reactive eosinophilia from other causes, such as parasitic infections or allergy, and evidence of end-organ damage [22]. According to World Health Organization the exclusion includes all neoplastic disorders in which eosinophils are part of the neoplastic clone. Excluded should be also T cell population with aberant phenotype and abnormal cytokine production [7], recently considert also as „lymphocytic“ variants of the HES [42]. HES has to be reclassified as chronic eosinophilic leukemia (CEL) when there is evidence for clonality based on the presence of chromosomal abnormalities or inactivation in female patients [7]. The successful empiric treatment of patients with tyrosine kinase inhibitor imatinib (Glivec) suggested the presence of an imatinib-sensitive tyrosine kinase inhibitor. The identification of a specific intersticial chromosoma deletion del(4)(q12;q12) creating the FIP1L1-PDGFRA fusion gene confirmed this hypothesis. Patients carrying this gene should be reclassified as CEL and detection of this gene is a positive predictor for response to imatinib therapy [11,45]. Effective doses of imatinib are 100 mg/day. The side effects are minimal. The only exception is an acute left ventricular dysfunction which has been reported in three patients within the first week of treatment with imatinib [36,38]. Imatinib has been successfully used also in some patients with the constitutively activated thyrosine kinase ETV6-PDGFRβ [1] and in systemic mast cell disease associated with eosinophilia [35]. Other therapeutical options for HES/CEL have been mentioned. The resistence to imatinib and the possibilities how to overcome it are discussed.

Key words:
hypereosinophilia - chronic eosinophilic leukemia - imatinib


Sources

1. Apperley JF, Gardebas M, Melo JV et al. Response to imatinib mesylate in patients with chronic myeloproliferative disease with rearrangements of the platelet-derived growth factor receptor beta. N Engl J Med 2002; 347: 481-487.

2. Ascione L, DeMichele M, Accadia M et al. Reversal of cardiac abnormalities in a young man with idiopathic hypereosinophilic syndrome using a tyrosine kinase inhibitor. Eur J Echocardiogr 2004; 5: 386-390.

3. Ault P, Cortes J, Koller C et al. Response of idiopathic hypereosinophilic syndrome to treatment with imatinib mesylate. Leuk Res 2002; 26: 881-884.

4. Bain BJ. Eosinophilic leukaemias and the idiopathic hypereosinophilic syndrome. Br J Haematol 1996; 95: 2-9.

5. Bain BJ. Hypereosinophilia. Curr Opin Hematol 2000; 7: 21-25.

6. Bain BJ. Cytogenetic and molecular genetic aspects of eosinophilic leukaemias. Br J Haematol 2003; 122: 173-179.

7. Bain BJ, Pierre R, Imbert M et al. Chronic eosinophilic leukaemia and the hypereosinophilic syndrome. In: Jaffe ES, Harris NL, Stein H et al. World Health Organization classification of tumors: Pathology and genetics of tumours of the haematopoietic and lymphoid tissues. Lyon, France: IARC Press 2001: 1201-1214.

8. Bonaventure C, Mastroianni B, Alessio A et al. Hypereosinophilie paraneoplasique associée à un carcinome hepatocellulaire. Gastroenterol Clin Biol 2003; 27: 1167-1169.

9. Brigden ML. A practical workup for eosinophilia. You can investigate the most likely causes right in your office. Postgrad Med 1999; 105: 207-210.

10. Brito-Babapulle F. The eosinophilias, including the idiopathic hypereosinophilic syndrome. Br J Haematol 2003; 121: 203-223.

11. Cools J, DeAngelo D, Gotlib J et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 2003; 348: 1201-1214.

12. Cools J, Stover EH, Boulton CL et al. PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFRα-induced myeloproliferative disease. Cancer Cell 2003; 3: 459-469.

13. Cools J, Stover EH, Wlodarska I et al. The FIP1L1-PDGFRα kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia. Curr Opin Hematol 2003; 11: 51-57.

14. Cortes J, Ault P, Koller C et al. Efficacy of imatinib mesylate in treatment of idiopathic hypereosinophilic syndrome Blood 2003; 101: 4714-4716.

15. Cortes J, O´Brien S, Kantarjian H. Discontinuation of imatinib therapy after achieving a molecular response. Blood 2004; 104: 2204-2205.

16. Cooper MA, Akard LP, Thompson JM et al. Hypereosinophilic syndrome: long-term remission following allogeneic stem cell transplant in spite of transient eosinophilic post-transplant. Am J Hematol 2005; 78: 33-36.

17. Garret JK, Jameson SC, Thomson B et al. Anti-interleukin-5 (mepolizumab) therapy for hypereosinophilic syndromes. J Allergy Clin Immunol 2004; 113: 115-119.

18. Golub TR, Barker GF, Lovett M et al. Fusion of PDGF receptor beta to a novel els-like gene, tel in chronic myelomonocytic leukemia with t (5;12) chromosomal translocation. Cell 1994; 77: 307-316.

19. Gudmondsson GS, Ohr J, Leya F et al. An unusual case of recurrent Löffler endomyocarditis of the aortic valve. Arch Pathol Lab Med 2003; 127: 606-609.

20. Gleich GJ, Leiferman KM, Pardanani A et al. Treatment of hypereosinophilic syndrome with imatinib mesylate. Lancet 2002; 359: 1577-1578.

21. Hardy WR, Anderson RE The hypereosinophilic syndromes. Ann Intern Med 1968; 68: 1220-1229.

22. Chusid MJ, Dale DC, West BC et al. The hypereosinophilic syndrome: analysis of fourteen cases with review of the literature. Medicine (Baltimore) 1975; 54: 1-27.

23. Inhorn RC, Aster JC, Roach SA et al. A syndrome of lymphoblastic lymphoma, eosinophilia and myeloid hyperplasia/malignancy associated with t (8;13) (p 11; q 11): description of distinctive clinico-pathologic entity. Blood 1995; 85: 1881-1887.

24. Kim YJ, Prussin C, Martin B et al. Rebound eosinophilia after treatment of hypereosinophilic syndrome and eosinophilic gastroenteritis with monoclonal anti-IL-5 antibody SCH55700. J Allergy Clin Immunol 2004; 114: 1449-1455.

25. Klion AD, Law MA, Noel P et al. Safety and efficacy of the monoclonal anti-interleukin-5 antibody SCH55700 in the treatment of patients with hypereosinophilic syndrome. Blood 2004; 103: 2939-2941.

26. Klion AD, Robyn J, Akin C et al. Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variants of hypereosinophilic syndrome. Blood 2004; 103: 473-478.

27. Krejsek J, Kopecký O. Klinická imunologie. Hradec Králové: Nucleus 2004.

28. Leblond P, Lepers S, Thebaud E et al. Le syndrome d´hypereosinophilie essentielle: à propos d´un cas chez un nourrisson. Arch Pediatr 2004; 11: 219-222.

29. Luppi M, Marasca R, Morselli M et al. Clonal nature of hypereosinophilic syndrome. Blood 1994; 84: 349-350.

30. MacDonald D, Aguiar RCT, Mason PJ et al. A new myeloproliferative disorder associated with chromosomal translocation involving 8p11: A review. Leukemia 1995; 9: 1628-1630.

31. MacDonald D, Reiter A, Cross NCP. The 8p11 myeloproliferative syndrome: a distinct clinical entity caused by constitutive activation of FGFR1. Acta Haematol 2002; 107: 101-107.

32. Maruyoshi H, Nakatani S, Yasumura Y et al. Löffler´s endocarditis associated with unusual ECG change mimicking posterior myocardial infarction. Heart-Vessels 2003; 18: 43-46.

33. Nishie M, Tomiyama M, Kamijo M et al. Acute cholecystitis and duodenitis associated with Churg-Strauss syndrome. Hepatogastroenterology 2003; 50: 998-1002.

34. Orson FM. Intravenous immunoglobulin therapy supresses manifestations of the angioedema with hypereosinophilic syndrome. Am J Med Sci 2003; 326: 94-97.

35. Pardanani A, Elliot M, Li CY et al. Imatinib for systemic mast-cell disease. Lancet 2003; 362: 535-537.

36. Pardanani A, Reeder T, Porrata LF et al. Imatinib therapy for hypereosinophilic syndrome and other eosinophilic disorders. Blood 2003; 101: 3391-3397.

37. Parrillo JE, Fauci AS, Wolff SM. Therapy of hypereosinophilic syndrome. Ann Intern Med 1978; 89: 167-172.

38. Pitini V, Arrigo C, Azzarello D et al. Serum concentration of cardiac Troponin T in patients with hypereosinophilic syndrome treated with imatinib is predictive of adverse outcomes. Blood 2003; 102: 3456-3457.

39. Pitini V, Teti D, Arrigo C et al. Alemtuzumab therapy for idiopathic hypereosinophilic syndrome with abnormal T cells: a case report. Br J Haematol 2004; 127: 474.

40. Plötz SG, Simon HU, Darson V et al. Use of an anti-interleukin-5 antibody in the hypereosinophilic syndrome with eosinophilic dermatitis. N Engl J Med 2003; 349: 2334-2339.

41. Rosenberg ME. Mechanisms of disease: eosinophilia. N Engl J Med 1985; 313: 1485-1492.

42. Roufosse F, Cogan E, Goldman M. The hypereosinophilic syndrome revisited. Annu Rev Med 2003; 54: 169-184.

43. Sefcick A, Sowter D, DasGusta E et al. Alemtuzumab therapy for refractory idiopathic hypereosinophilic syndrome. Br J Haematol 2004; 124: 558-559.

44. Schaller JL, Burkland GA. Rapid and complete control of idiopathic hypereosinophilia with imatinib mesylate. Med Gen Med 2001; 3: 9.

45. Steer EJ, Cross NCP. Myeloproliferative disorders with translocations of chromosome 5q 31-35; role of the platelet-derived growth factor receptor beta. Acta Haematol 2002; 107: 113-122.

46. Tefferi A, Pardanani A. Imatinib treatment-induced cardiomyopathy in hypereosinophilic syndrome. Blood 2003; 102: 3457.

47. Vandenberghe P, Wlodarska J, Michaux L et al. Clinical and molecular features of FIP1L1-PDGFRA(+) chronic eosinophilic leukemia. Leukemia 2004; 18: 734-742.

48. Weller PF, Bubley G. The idiopathic hypereosinophilic syndrome. Blood 1994; 83: 2759-2779.

49. Zittoun J, Farcet JP, Marquet J et al. Cobalamin (vitamin B12) and B12 binding proteins in hypereosinophilic syndromes and secondary eosinophilia. Blood 1984; 63: 779-783.

Labels
Diabetology Endocrinology Internal medicine

Article was published in

Internal Medicine

Issue 12

2005 Issue 12

Most read in this issue
Topics Journals
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#